Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 162 participants.
Also called NCT02347111
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 162 participants
- Registry
-
NCT02347111
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT02347111. Randomized; no masking; primary purpose treatment. Start 2020-12-31 (actual); primary completion 2026-06-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- Flecainide
- Intervention (Drug)
- Sotalol
- Lead sponsor
- University of Illinois Chicago
- Collaborator
- Medtronic
Record details
- Record id
cardio:ct-nct02347111- Content hash
3666de46679f32247e6483e3e60cbc4866e41988a91120f855e3d1d0f7ce7fd0